Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose Daptomycin PK/PD in Septic Shock
NCT02508350Unknown
- Sponsor
- Zhongda Hospital, Southeast University
- Start
- Jan 2015
- Primary completion
- Dec 2015
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of daptomycin in septic shock, sponsored by Zhongda Hospital, Southeast University. Primary endpoints: Area under the curve (AUC) / Minimum inhibitory concentration (MIC) at 6 days and Peak concentration (Cmax) / Minimum inhibitory concentration (MIC) at 6 days. Status: unknown.
02
Drugs
daptomycin
03
Conditions
septic shock
Beyond the preview
Go deeper on NCT02508350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02508350.